



ARE YOU READING IT'S FINE BETWEEN THE FINES?

Your patients with Alagille syndrome may say they are fine, but are they really? Dig deeper at their next appointment and show patients what is possible if they could LIV with less cholestatic pruritus.¹⁻⁴

Individual experiences may vary.

EMMA

Real patient living
with cholestatic pruritus
in Alagille syndrome

INDICATION

LIVMARLI is indicated for the treatment of cholestatic pruritus in patients who are 3 months of age and older with Alagille syndrome.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Please see Important Safety Information throughout and full [Prescribing Information](#).

 **Livmarli**[®]
(maralixibat) oral solution

On average,
people surveyed say **"I'M FINE"**

14 times per week
////////////////////

but *mean it* just

20% of the time⁵
////////////////////

S FINE IT'S FINE IT'S FINE IT'S FINE
IT'S FINE IT'S FINE IT'S FINE IT'S FINE
IT'S FINE IT'S FINE IT'S FINE IT'S FINE
HE FINE IT'S FINE IT'S FINE IT'S FINE
ALWAYS RUBS
HIS EYES
IT'S FINE IT'S FINE IT'S FINE IT'S FINE



FINLEY

Real patient living with
Alagille syndrome and his
parents, Jay and Dani

Individual experiences may vary.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Treatment-emergent elevations or worsening of liver tests have occurred. Obtain baseline liver tests and monitor during treatment; monitor also for liver-related adverse reactions and signs of hepatic decompensation. Dose reduction or treatment interruption may be considered if abnormalities occur. Permanently discontinue if persistent liver test abnormalities, clinical hepatitis upon rechallenge, or hepatic decompensation occur.

2 Please see Important Safety Information throughout and full Prescribing Information.



THE FACT IS, PATIENTS AND CAREGIVERS ARE NORMALIZING SYMPTOMS

Many patients are not bringing up their cholestatic pruritus and the need for a treatment with their physician

In one survey of patients with Alagille syndrome, nearly **30%** said they talked to their doctor about cholestatic pruritus, but not in detail. However, **~20%** said cholestatic pruritus was not discussed at all.⁶



“ I would tell myself, ‘It’s fine, maybe he just has allergies,’ or ‘Maybe it’s the weather.’ Everyone around us downplayed it so it became normal for us. ”

–TERISA,
mom to Tyler, a patient
with Alagille syndrome



“ We really didn’t want to acknowledge the itching. We just found ways around it. We would keep the house cool. We would wash her sheets every day. ”

–MICHELLE,
mom to Téa, a patient
with Alagille syndrome



“ It wasn’t until I found relief that I realized how bad it was and how important it is to talk to your doctor. I was always scared to talk about my cholestatic pruritus because I didn’t know what else could be done. Now I understand—I wasn’t fine. ”

–ABBY,
living with Alagille syndrome

Individual experiences may vary.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS

Fat-Soluble Vitamin (FSV) Deficiency: Obtain baseline levels and monitor during treatment. Supplement vitamins if deficiency is observed. Consider interrupting LIVMARLI if bone fractures or bleeding occur.

4 Please see Important Safety Information throughout and full [Prescribing Information](#).

 **Livmarli**[®]
(maralixibat) oral solution

THE *SIGNS* BETWEEN THE *FINES*

You may hear these phrases from your patients and caregivers when discussing cholestatic pruritus in Alagille syndrome. Below are discussion questions that may foster a deeper conversation.^{7,8}

IT'S *FINE*.

- I am glad you are feeling fine right now, but do you feel itchy or experience a “flare-up” at times?
- How often do you find yourself scratching?
- Do you ever make clothing choices based on how your skin feels?
- Are you using topical lotions or other medicines to control the itch?

SLEEP IS *FINE*.

- What does a typical night’s sleep look like for you? Do you ever wake up to scratch?
- Tell me how often you sleep through the night without itching
- How did you sleep last night?

SCHOOL IS *FINE*.

- Are you ever distracted during the school day? Does the itchiness interrupt your ability to learn?
- Do you catch yourself scratching without realizing it?
- Does your teacher comment about your itching?

SOCIAL LIFE IS *FINE*.

- Do you ever miss out on doing things with family or friends due to your itch?
- Do your friends know about your itching?
- Has anyone ever pointed out that you tend to scratch?
- Do you ever feel embarrassed by your itching?

AFTER-SCHOOL ACTIVITIES AND/OR WORK ARE *FINE*.

- Has scratching ever interfered with your extracurricular activities or work?
- Do you ever decide not to attend an activity or work because you are too itchy that day?



Initiate the conversation and inquire further at each appointment to effectively assess and treat your patients’ cholestatic pruritus.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

5 Please see Important Safety Information throughout and full [Prescribing Information](#).



Up to 88% of patients with Alagille syndrome experience cholestatic pruritus⁹

In the treatment of Alagille syndrome...

REDE **FINE** EXPECTATIONS in cholestatic pruritus

LIVMARLI is indicated for the treatment of cholestatic pruritus in patients who are 3 months of age and older with Alagille syndrome.¹

To hear real patients open up about life with cholestatic pruritus, visit LIVMARLIhcp.com/between-the-fines/



Individual experiences may vary.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Treatment-emergent elevations or worsening of liver tests have occurred. Obtain baseline liver tests and monitor during treatment; monitor also for liver-related adverse reactions and signs of hepatic decompensation. Dose reduction or treatment interruption may be considered if abnormalities occur. Permanently discontinue if persistent liver test abnormalities, clinical hepatitis upon rechallenge, or hepatic decompensation occur.

6 Please see Important Safety Information throughout and full [Prescribing Information](#).

ANY LEVEL OF CHOLESTATIC PRURITUS DESERVES ATTENTION

LIVMARLI can help your patients LIV It Up with less itch¹⁻⁴



First and only treatment to provide **early improvements*** in cholestatic pruritus with **long-term impact**^{2,10,11}



>6 years of clinical data plus real-world use^{1,12,13}



Exceptional access and patient support

*Cholestatic pruritus improvements were seen at the first assessment (Week 3).

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Gastrointestinal Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions in patients treated with LIVMARLI. Consider reducing the dosage or interrupting treatment if a patient experiences persistent diarrhea or abdominal pain.

Please see Important Safety Information throughout and full Prescribing Information.

References: **1.** LIVMARLI® (maralixibat) oral solution. Prescribing Information. Mirum Pharmaceuticals, Inc. **2.** Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. *Lancet*. 2021;398(10311):1581-1592. doi:10.1016/S0140-6736(21)01256-3 **3.** Gonzales E, Sturm E, Stormon M, et al. Durability of treatment effect with long-term maralixibat in children with Alagille syndrome: 4-year safety and efficacy. Presented at: American Association for the Study of Liver Diseases Annual Meeting: The Liver Meeting; November 8-12, 2019; Boston, MA. **4.** Data on file. REF-00100. Mirum Pharmaceuticals, Inc. **5.** Facts about mental health. Mental Health Foundation. Accessed June 7, 2024. <https://www.mentalhealth.org.uk/sites/default/files/2022-06/MHF-facts-about-mental-health-posters-colour.pdf> **6.** Data on file. REF-01349. Mirum Pharmaceuticals, Inc. **7.** Kamath BM, Abetz-Webb L, Kennedy C, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. *Pediatr*. 2018;11(1):69-82. doi:10.1007/s40271-017-0266-4 **8.** Data on file. REF-01343. Mirum Pharmaceuticals, Inc. **9.** Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. *J Pediatr Gastroenterol Nutr*. 2018;67(2):148-156. doi:10.1097/MPG.0000000000001958 **10.** Sokol RJ, Gonzales EM, Kamath BM, et al. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. *Hepatology*. 2023;78(6):1698-1710. **11.** Data on file. REF-00342. Mirum Pharmaceuticals, Inc. **12.** Data on file. REF-01111. Mirum Pharmaceuticals, Inc. **13.** Raman RK, Garner W, Vig P, Tucker E. An integrated analysis of long-term clinical safety in maralixibat treated participants with Alagille syndrome. Poster presented at: European Association for the Study of the Liver (EASL): International Liver Congress; June 23-26, 2021.

For more information,
please contact me or visit
LIVMARLIhcp.com/between-the-fines/